Supernus Pharma Stock Price, News & Analysis

Supernus Pharmaceuticals (Nasdaq: SUPN) provided regulatory updates regarding SPN-812 for ADHD and SPN-830 for Parkinson's disease. The FDA issued a Complete Response Letter (CRL) for SPN-812, indicating the application is not ready for approval due to facility-related issues, but no clinical efficacy or safety concerns were raised. Additionally, SPN-830 received a Refusal to File letter, requiring further documentation. The company plans to engage with the FDA to address these issues. Supernus reiterated its 2020 financial guidance, projecting net product sales between $500 million and $525 million.

Supernus Pharmaceuticals (SUPN) reported Q3 2020 revenues of $155.1 million, a 52% increase from Q3 2019, with net product sales at $152.1 million. Operating earnings reached $56.1 million, up from $39.7 million a year earlier. The company is set to launch SPN-812 for ADHD treatment in January 2021, pending FDA approval, with topline data from its Phase III trial expected in Q1 2021. Full-year net product sales guidance increased to $500-$525 million. Cash reserves stood at $740.1 million as of September 30, 2020.

Supernus Pharmaceuticals (Nasdaq: SUPN) will report its Q3 2020 business results on November 3, 2020, after 5:00 p.m. ET. A conference call hosted by President and CEO Jack Khattar will follow on November 4, 2020, at 9:00 a.m. ET, allowing for a discussion of the results and a Q&A session. The call can be accessed via dial-in or live webcast on the company's website. Supernus is focused on CNS diseases and markets several products, including Trokendi XR and Oxtellar XR, while developing new treatments for ADHD and depression.

Supernus Pharmaceuticals Announces CFO Transition

Greg Patrick will retire as Chief Financial Officer of Supernus Pharmaceuticals, effective October 12, 2020. James Kelly, formerly CFO at Vanda Pharmaceuticals, will assume the role, bringing over 25 years of experience in the biopharmaceutical industry. Kelly is expected to strengthen Supernus's financial operations and strategy to drive growth. Patrick will remain as an advisor to ensure a smooth transition. This leadership change highlights Supernus's commitment to maintaining a solid financial foundation while advancing its product pipeline focused on CNS diseases.

Supernus Pharmaceuticals will present an overview and update at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 2:00 p.m. ET. Investors can schedule virtual meetings with management during the conference. A live webcast of the presentation will be available on the company's website, with a replay accessible for 60 days post-conference. Supernus focuses on developing products for central nervous system diseases, including treatments for migraine, epilepsy, Parkinson’s disease, and chronic sialorrhea.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced its participation in the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 9:20 a.m. ET. The company will provide an overview and update, along with hosting investor meetings. Interested investors can arrange virtual meetings by contacting the conference coordinator. A live webcast of the presentation will be available on the company's website, with an archived replay accessible for 60 days post-conference.

Supernus focuses on treatments for CNS diseases and has multiple marketed products and development candidates.

Supernus Pharmaceuticals (SUPN) reported Q2 2020 revenues of $126.7 million, with net product sales of $89.7 million for Trokendi XR® and $23.7 million for Oxtellar XR®. Operating earnings reached $45.5 million, showing a 21% growth year-over-year. The company completed the acquisition of a CNS portfolio and established a collaboration with Navitor Pharmaceuticals for SPN-820. It expects net product sales for 2020 to be between $460 million and $500 million, with operating earnings between $90 million and $110 million.

Supernus Pharmaceuticals reported estimated total revenue of $126.7 million for Q2 2020, marking a 21% increase from 2019. The net product sales for Trokendi XR and Oxtellar XR reached $113.4 million, reflecting an 11% increase. This growth was driven partly by $10.6 million from the acquisition of US WorldMeds’ CNS portfolio on June 9, 2020. A conference call to provide detailed results will be held on August 19, 2020.

Supernus Pharmaceuticals (NASDAQ: SUPN) announced a lawsuit against Apotex for infringing on nine patents related to its antiepileptic drug Oxtellar XR. The suit was filed in the U.S. District Court for New Jersey after Apotex submitted an ANDA to the FDA, seeking to market a generic version before patent expiration on April 13, 2027. This legal action allows Supernus a 30-month stay on FDA approval of Apotex's generic. Previously, Supernus successfully defended its patent rights against other generic competitors. The company remains focused on CNS disease treatments.